Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Surg Oncol Clin N Am. 2011 Jan;20(1):1–17. doi: 10.1016/j.soc.2010.09.007

Table 4.

Five-year survival rates for stage III (nodal metastases) patients stratified by number of metastatic nodes, primary tumor ulceration, and nodal tumor burden (microscopic or macroscopic) (n=2313).

Primary tumor ulceration No. of Nodal Micrometastases % ±S.E. (n=1,872) No. of Nodal Macrometastases % ± S.E. (n=441)
1 2–3 ≥4 1 2–3 ≥4
Absent 81.5 ± 1.9 (777) 73.2 ± 3.7 (246) 38.0 ± 8.5 (46) 51.6 ± 7.2 (75) 46.6 ± 7.9 (67) 45.4 ± 9.1 (50)
Present 56.6 ± 2.9 (531) 53.9 ± 4.2 (223) 34.0 ± 8.3 (49) 49.4 ± 6.2 (88) 37.7 ± 6.2 (93) 29.2 ± 6.7 (68)

From Balch CM, Gershenwald JE, Soong SJ, et al: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452, 2010; with permission.